Among these, PDCD1 was chosen for further investigation due to its significant role in immune checkpoint regulation and its growing importance in drug resistance pathways, especially in the context of ibrutinib-treated chronic lymphocytic leukemia (CLL). The gene discussed is PDCD1; the disease is B-cell chronic lymphocytic leukemia.